当前位置： SCI文献检索 > CANCER期刊下所有文献 > Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer.

Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer.

Abstract：

:The authors treated 32 patients with Stage IIIB or IV non-small cell lung cancer (NSCLC) with an outpatient regimen of edatrexate (10-ethyl-10-deaza-aminopterin) (10-EdAM) on days 1 and 8, cyclophosphamide on day 1, and cisplatin on day 1, repeated every 3 weeks with dose modification. The 22 men and 10 women (median age, 57 years of age) had no prior chemotherapy and a Zubrod performance status less than or equal to 2. A schedule with initial doses of 80 mg/m2, 800 mg/m2, and 80 mg/m2, respectively, yielded a 47% major response rate with two complete responses (95% confidence interval [CI], 25% to 70%), but it also yielded significant stomatitis and myelosuppression. A schedule with reduced starting doses (70 mg/m2, 700 mg/m2, and 70 mg/m2) was better tolerated, but dropped the major response rate to 27% with no complete responses (95% CI, 11% to 52%). Median survival time was 39 weeks for all 30 evaluable patients without a significant difference between the treatment groups (which were comparable in patient characteristics). Major response, however, was associated with longer survival time than minor response or no change (P = 0.024) or progressive disease (P = 0.001) (median survival times, 55, 39, and 27 weeks, respectively). When the doses delivered were compared, patients treated with the reduced dose schedule received less mean 10-EdAM per course (P = 0.01), although the doses of cyclophosphamide and cisplatin were comparable to the original dose schedule for the second course and thereafter. These results suggest that this three-drug regimen may have synergistic antitumor effects, with a steep dose-response relationship, particularly with 10-EdAM. With amelioration of the dose-limiting stomatitis of 10-EdAM, it seems possible to maximize the antitumor effects of this regimen.

journal_name

Cancer

journal_title

Cancer

authors

Lee JS,Libshitz HI,Fossella FV,Murphy WK,Pang AC,Lippman SM,Shin DM,Dimery IW,Glisson BS,Hong WK

doi

10.1002/1097-0142(19910901)68:5<959::aid-cncr28206

subject

Has Abstract

pub_date

1991-09-01 00:00:00

pages

959-64

issue

eissn

0008-543X

issn

1097-0142

journal_volume

pub_type

临床试验,杂志文章

在线工具

Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer.